Tirzepatide U.S. label context · version 1
This page preserves this version's wording and source pins. Open the current profile →
What does the U.S. product label say?
Zepbound · Read September 15, 2026 · Preserved label summary 1
Which population and use does the label cover?
The cited Zepbound label covers long-term weight reduction in adults with obesity, or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity. Both indications are described alongside diet and physical activity. This is a product-specific account, separate from Mounjaro labeling. Label: 1 ↗
Which safety limits matter?
The boxed warning reports thyroid C-cell tumors in rats, with uncertain human relevance. Contraindications include a personal or family history of medullary thyroid carcinoma, MEN 2 and serious hypersensitivity. Warnings address severe gastrointestinal reactions, kidney injury from volume depletion, gallbladder disease, pancreatitis, hypoglycemia, diabetic retinopathy complications and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02
Label ZIP SHA-256: 4fe25d4173ba662adc2b4ac0653c09643bc7a9e883557286abe2c5d36f19d87e. Extracted XML SHA-256: 7c40611952c42e85d4688669dae2a5529cd563e0e857fdb23e411a8f7d8b0f14.